SMMT Q4 2022 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$705-99.7% YoY

Gross Profit

-$595,000-84397.2% margin

Operating Income

-$20M-2879290.8% margin

Net Income

-$19M-2727517.7% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-99.7%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$664M

Total Liabilities

$538M

Stockholders' Equity

$127M

Cash & Equivalents

$349M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$705	$251,000	-99.7%
Gross Profit	-$595,000	$251,000	-337.1%
Operating Income	-$20M	-$26M	+22.1%
Net Income	-$19M	-$26M	+25.3%

Revenue Segments

License and Service

$4M100%